On a roll, Apellis adds positive PhII C3 data for AMD drug, preps for PhIII
Just days after grabbing a $60 million round to fund a Phase III program for a rival therapy to Alexion’s Soliris, Louisville, KY-based Apellis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
